Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment (Q39815389)

14 September 2017

Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment (English)

1 reference

14 September 2017

2

Keith T Flaherty

1 reference

14 September 2017

1

Keiran S M Smalley

1 reference

PubMed ID

19663727

14 September 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

14 September 2017

1 reference

14 September 2017

5

1 reference

14 September 2017

6

1 reference

14 September 2017

775-778

1 reference

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

14 September 2017

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

21 January 2018

Targeted cancer therapy

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

21 January 2018

1 reference

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival

21 January 2018

1 reference

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

Getting to the stem of chronic myeloid leukaemia

21 January 2018

1 reference

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

21 January 2018

1 reference

Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth

21 January 2018

1 reference

mTOR is activated in the majority of malignant melanomas

21 January 2018

1 reference

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.56

1 reference

14 September 2017

1 reference

PubMed ID

19663727